Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer.
Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.
